Targeted-release budesonide for patients with IgA nephropathy
Drug and Therapeutics Bulletin · 2025
DOI: 10.1136/dtb.2024.000071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Therapeutics Bulletin, 2025. Verfasst von Isaac Chung und 1 weiteren Autor:innen. Beteiligte Einrichtung: Blood Pressure Unit, St George's University Hospitals NHS Trust, London, UK. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Budesonide. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Commentary on: Lafayette R, Kristensen J, Stone A, et al . Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet . 2023;402:859–70. Series co-ordinator: Dr Teck Khong, DTB Associate Editor, Clinical Pharmacology, St George’s, University of London, UK
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blood Pressure Unit, St George's University Hospitals NHS Trust, London, UK.
- Blood Pressure Unit, St George's University Hospitals NHS Trust, London, UK tkhong@sgul.ac.uk.
- Clinical Pharmacology, St George's University of London, London, UK.
Zitieren
APA
Chung, I., & Khong, T. K. (2025). Targeted-release budesonide for patients with IgA nephropathy. Drug and Therapeutics Bulletin. https://doi.org/10.1136/dtb.2024.000071
Vancouver
Chung I, Khong TK. Targeted-release budesonide for patients with IgA nephropathy. Drug and Therapeutics Bulletin. 2025. doi:10.1136/dtb.2024.000071
BibTeX
@article{Chung2025,
author = {Chung, Isaac and Khong, Teck K},
title = {Targeted-release budesonide for patients with IgA nephropathy},
journal = {Drug and Therapeutics Bulletin},
year = {2025},
doi = {10.1136/dtb.2024.000071}
}
EUVIMED